Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.
;
Miriam
Dwek
;
Diana M
Eccles
;
A Heather
Eliassen
;
Peter A
Fasching
;
Jonine
Figueroa
;
Henrik
Flyger
;
Lin
Fritschi
;
Manuela
Gago-Dominguez
;
Susan M
Gapstur
;
Montserrat
García-Closas
;
José A
García-Sáenz
;
Mia M
Gaudet
;
Graham G
Giles
;
Mark S
Goldberg
;
David E
Goldgar
;
Pascal
Guénel
;
Christopher A
Haiman
;
Niclas
Håkansson
;
Per
Hall
;
Patricia A
Harrington
;
Steven N
Hart
;
Mikael
Hartman
;
Peter
Hillemanns
;
John L
Hopper
;
Ming-Feng
Hou
;
David J
Hunter
;
Dezheng
Huo
;
ABCTB Investigators
;
Hidemi
Ito
;
Motoki
Iwasaki
;
Milena
Jakimovska
;
Anna
Jakubowska
;
Esther M
John
;
Rudolf
Kaaks
;
Daehee
Kang
;
Renske
Keeman
;
Elza
Khusnutdinova
;
Sung-Won
Kim
;
Peter
Kraft
;
Vessela N
Kristensen
;
Allison W
Kurian
;
Loic
Le Marchand
;
Jingmei
Li
;
Annika
Lindblom
;
Artitaya
Lophatananon
;
Robert N
Luben
;
Jan
Lubiński
;
Arto
Mannermaa
;
Mehdi
Manoochehri
;
Siranoush
Manoukian
;
Sara
Margolin
;
Shivaani
Mariapun
;
Keitaro
Matsuo
;
Tabea
Maurer
;
Dimitrios
Mavroudis
;
Alfons
Meindl
;
Usha
Menon
;
Roger L
Milne
;
Kenneth
Muir
;
Anna Marie
Mulligan
;
Susan L
Neuhausen
;
Heli
Nevanlinna
;
Kenneth
Offit
;
Olufunmilayo I
Olopade
;
Janet E
Olson
;
Håkan
Olsson
;
Nick
Orr
;
Sue K
Park
;
Paolo
Peterlongo
;
Julian
Peto
;
Dijana
Plaseska-Karanfilska
;
Nadege
Presneau
;
Brigitte
Rack
;
Rohini
Rau-Murthy
;
Gad
Rennert
;
Hedy S
Rennert
;
Valerie
Rhenius
;
Atocha
Romero
;
Matthias
Ruebner
;
Emmanouil
Saloustros
;
Rita K
Schmutzler
;
Andreas
Schneeweiss
;
Christopher
Scott
;
Mitul
Shah
;
Chen-Yang
Shen
;
Xiao-Ou
Shu
;
Jacques
Simard
;
Christof
Sohn
;
Melissa C
Southey
;
John J
Spinelli
;
Rulla M
Tamimi
;
William J
Tapper
;
Soo H
Teo
;
Mary Beth
Terry
;
Diana
Torres
;
Thérèse
Truong
;
Michael
Untch
;
Celine M
Vachon
;
Christi J
van Asperen
;
Alicja
Wolk
;
Taiki
Yamaji
;
Wei
Zheng
;
Argyrios
Ziogas
;
Elad
Ziv
;
Gabriela
Torres-Mejía
;
Thilo
Dörk
;
Anthony J
Swerdlow
;
Ute
Hamann
;
Marjanka K
Schmidt
;
Alison M
Dunning
;
Paul DP
Pharoah
;
Douglas F
Easton
;
Maartje J
Hooning
;
John WM
Martens
;
Antoinette
Hollestelle
;
(2020)
Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.
SCIENTIFIC REPORTS, 10 (1).
9688-.
ISSN 2045-2322
DOI: 10.1038/s41598-020-65665-y
In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR = 1.035, 95% CI = 0.859-1.246, P = 0.718 and OR = 0.798, 95% CI = 0.482-1.322, P = 0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Thus, although involved in breast cancer progression, HOXB13 is not a material breast cancer susceptibility gene.
-
picture_as_pdf - Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution 3.0